A CDC advisory panel voted to recommend RSV vaccines for at-risk adults 50 to 59, a sought-after expansion by vaccine makers ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

Infants aged 2 years or younger, pregnant women and adults aged older than 50 years qualify for an FDA-approved RSV vaccine. Abrysvo for pregnant women had the highest administration rate since ...

RSV is a common virus that can be deadly and is most dangerous for the very young and the elderly. U.S. drugmaker Pfizer and the UK's GSK are each banking on strong sales of their RSV shots ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

Just 1 in 10 older adults who participated in the study had received an RSV vaccine during the first season when RSV vaccines were available, from 2023 to 2024, the data showed.

or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended indication includes the prevention of lower respiratory tract disease caused by RSV in individuals 18 to 59 years ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO ®, the ...